trans-Dihydrorofecoxib | 308364-86-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: trans-Dihydrorofecoxib
• 英文别名: (3S,4S)-4-(4-methylsulfonylphenyl)-3-phenyloxolan-2-one
• CAS: 308364-86-5
• 化学式: C₁₇H₁₆O₄S
• 分子量: 316.378
• InChiKey: PHCFUFKRCHEUTJ-HZPDHXFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  trans-Dihydrorofecoxib 在 sodium hydroxide 作用下， 以60%的产率得到Rofecoxib-threo-3,4-dihydrohydroxy acid
  参考文献：
  名称：

  Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™)

  摘要：

  Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx(TM)) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-I nor contributes significantly to the inhibition of COX-2. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00538-2
• 作为产物：
  描述：

  罗非昔布 在 palladium on activated charcoal 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 乙醇 、 乙酸乙酯 为溶剂， 生成 trans-Dihydrorofecoxib
  参考文献：
  名称：

  Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™)

  摘要：

  Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx(TM)) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-I nor contributes significantly to the inhibition of COX-2. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00538-2

文献信息

• Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™)
  作者：Deborah A Nicoll-Griffith、James A Yergey、Laird A Trimble、José M Silva、Chun Li、Nathalie Chauret、Jacques Yves Gauthier、Erich Grimm、Serge Léger、Patrick Roy、Michel Thérien、Zhaoyin Wang、Peppi Prasit、Robert Zamboni、Robert N Young、Christine Brideau、Chi-Chung Chan、Joseph Mancini、Denis Riendeau

  DOI：10.1016/s0960-894x(00)00538-2

  日期：2000.12

  Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx(TM)) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-I nor contributes significantly to the inhibition of COX-2. (C) 2000 Elsevier Science Ltd. All rights reserved.